Catalyst Wire Dossier Catalyst Wire Dossier

RI-002

intravenous immunoglobulin · ADMA Biologics, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for RI-002, covering 2016-10-05 to 2016-10-05. Get the full timeline:

Most recent: Clinical Trial Update: Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD) [Phase 3]

See pricing